8-K: Clene Inc. Announces Second Quarter 2024 Financial Results and Positive Clinical Updates for CNM-Au8

Clene Inc. reported its second quarter 2024 financial results, highlighting positive clinical data for its CNM-Au8 drug in ALS and Rett Syndrome, and regained Nasdaq compliance.

Summary

• Clene Inc. announced its second quarter 2024 financial results, reporting a net loss of $6.8 million, or $1.06 per share, compared to a net loss of $25.1 million, or $5.84 per share, for the same period in 2023.
• The company's cash and cash equivalents totaled $21.7 million as of June 30, 2024, and they expect this to fund operations into the fourth quarter of 2024.
• Clene presented positive long-term data for its CNM-Au8 treatment in ALS, showing improved survival and reduced neurofilament light (NfL) levels in a subset of patients.
• In an in vitro model of Rett Syndrome, CNM-Au8 demonstrated neuroprotective effects, improving neuronal health and mitochondrial respiration.
• The company submitted a briefing book to the FDA in advance of a Type C interaction planned for the third quarter of 2024 to discuss an accelerated approval pathway for CNM-Au8.
• Clene regained compliance with Nasdaq listing requirements after completing a 1-for-20 reverse stock split.

Sentiment

Score: 7

Explanation: The document presents positive clinical data for CNM-Au8, particularly in ALS, and the company has regained Nasdaq compliance. However, the company's financial position is weak, and they will need to raise additional capital. The sentiment is positive but tempered by financial concerns.

Positives

• CNM-Au8 demonstrated a significant reduction in the risk of death for ALS patients, with a hazard ratio of 0.431 compared to controls.
• The NfL responder subset showed a substantial 28% average reduction in NfL levels, indicating decreased axonal loss.
• CNM-Au8 showed promising results in an in vitro model of Rett Syndrome, suggesting potential for treating this rare disease.
• The company has sufficient cash to fund operations into the fourth quarter of 2024.
• Clene has successfully regained compliance with Nasdaq listing requirements.

Negatives

• Clene reported a net loss of $6.8 million for the second quarter of 2024.
• The company's cash and cash equivalents decreased from $35.0 million at the end of 2023 to $21.7 million as of June 30, 2024.
• Research and development expenses decreased year-over-year, primarily due to reimbursements from the NIH grant and lower clinical trial expenses.

Risks

• The company's ability to obtain FDA approval for CNM-Au8 is not guaranteed.
• Clene's financial resources are projected to last only into the fourth quarter of 2024, requiring additional funding.
• The clinical results for CNM-Au8 may not support further development or marketing approval.
• Actions of regulatory agencies could affect the initiation, timing, and progress of clinical trials and marketing approval.
• The company has a limited operating history and may face challenges in achieving commercial success for its drug candidates.

Future Outlook

Clene anticipates submitting a new drug application for CNM-Au8 later this year and expects its current resources to fund operations into the fourth quarter of 2024. The company also plans to publicly announce the topline FDA feedback following the conclusion of the Type C interaction.

Management Comments

• We are approaching our next FDA interaction focused on the regulatory path forward to potentially bring CNM-Au8 to people living with ALS, said Rob Etherington, President and CEO of Clene.
• With this imminent timing, we are optimistic about the possibility of submitting a new drug application later this year.
• Our utmost priority is to help patients and their families for whom time is critical.

Industry Context

This announcement is significant in the context of the neurodegenerative disease treatment landscape, where there is a high unmet need for effective therapies for diseases like ALS and Rett Syndrome. The positive clinical data for CNM-Au8 could position Clene as a key player in this space, especially if the FDA grants accelerated approval.

Comparison to Industry Standards

• The 60% decreased risk of death in ALS patients treated with CNM-Au8 is a notable result, comparing favorably to other experimental treatments in the ALS space.
• The 28% average reduction in NfL levels in the responder subset is a strong indicator of potential disease modification, which is a key goal in neurodegenerative disease research.
• The in vitro results for Rett Syndrome are promising, but further clinical trials are needed to confirm these findings in humans. Companies like Acadia Pharmaceuticals and Anavex Life Sciences are also developing treatments for Rett Syndrome, and Clene's results will be compared to their progress.
• Clene's cash position of $21.7 million is relatively low for a late-stage biopharmaceutical company, and they will need to raise additional capital to fund further development and commercialization. Companies like Amylyx Pharmaceuticals and Biogen, which have approved ALS treatments, have significantly larger cash reserves.

Stakeholder Impact

• Shareholders may see a positive impact from the positive clinical data and regained Nasdaq compliance, but the need for additional funding could dilute their holdings.
• Patients with ALS and Rett Syndrome may benefit from the potential approval of CNM-Au8.
• Employees may be impacted by the company's financial situation and potential restructuring.
• Creditors may be concerned about the company's financial position and ability to repay debts.

Next Steps

• Clene will participate in a Type C interaction with the FDA in the third quarter of 2024.
• The company plans to publicly announce the topline FDA feedback following the Type C interaction.
• Clene is optimistic about the possibility of submitting a new drug application later this year.
• The company will continue to enroll patients in the Expanded Access Program (EAP).

Key Dates

Keywords

CNM-Au8, ALS, Rett Syndrome, Neurodegenerative Diseases, FDA, Clinical Trials, NfL, Nasdaq, Biopharmaceutical, Mitochondrial Health